Multiple sclerosis and alopecia areata

Tada, Yasutake; Hamaguchi, Tetsuya; Ikeda, Yukio; Kazuya, T.; Yamada, Masako

doi:10.1016/j.jns.2017.08.3007

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tada et al conducted a study on 70 patients with MS and found that five patients (Male/Female = 4/1) were complicated with AA. Differently from our two cases, their patients developed AA after the onset of MS.…”

Section: Discussionmentioning

confidence: 99%

“…In the literature, only a few cases of association between AA and MS are reported. 3,4 Tada et al 3 Interestingly, AA has been recently hypothesized as a possible side effect of anti-CD52 monoclonal antibody alemtuzumab, which is used for treatment of relapsing-remitting MS. [5][6][7][8] In fact, AA had been reported during alemtuzumab therapy in five patients. The possible mechanism of secondary AA is a drug-induced selective lymphopenia, sparing self-antigen responsive T cells and autoimmune B cells, which could be the possible responsible cells of AA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Associations between alopecia areata and multiple sclerosis: a report of two cases and review of the literature

et al. 2019

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Associations between alopecia areata and multiple sclerosis: a report of two cases and review of the literature

et al. 2019

View full text Add to dashboard Cite

“…Earlier studies do not support an association of alopecia with MS. However, a study of 70 patients with MS reported on 5 cases of associated alopecia areata that developed after the onset of MS. 56 It is important to note that in addition to MS, all patients with alopecia areata had other comorbid autoimmune diseases such as Hashimoto’s thyroiditis, uveitis, bronchial asthma, and hives. Another case study reported a Caucasian female affected by alopecia Universalis, autoimmune thyroiditis, MS, and pelvic endometriosis.…”

Section: Discussionmentioning

confidence: 99%

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

Porwal

Salter

Patel

et al. 2022

J Cent Nerv Syst Dis

View full text Add to dashboard Cite

BACKGROUND There is currently limited literature addressing the reporting of alopecia in multiple sclerosis (MS) patients treated with disease-modifying therapies (DMTs). Anecdotal reports of hair thinning from patients on various DMTs prompted further investigation of a large database. OBJECTIVE To analyze total reports, source of reporting, age distribution, and sex distribution of alopecia associated with DMTs. METHODS FDA Adverse Event Reporting System (FAERS) public dashboard and OpenFDA database were analyzed for alopecia reports between January 1, 2009, and June 30, 2020, attributed to usage in MS of FDA approved DMTs. The main outcomes included total reports for each drug, age, sex distribution, and reporting source. OpenFDA data was used for statistical analyses including reporting odds ratios (ROR) and information components. RESULTS 8759 alopecia reports were identified among 44 114 adverse events in skin and subcutaneous tissue disorders (19.9%). 3701 (42.3%) with teriflunomide, 1675 (19.1%) with dimethyl fumarate, 985 (11.2%) with natalizumab, 926 (10.6%) with fingolimod, 659 (7.5%) with interferon beta-1a, 257 (2.9%) with glatiramer acetate, 243 (2.8%) with ocrelizumab, 124 (1.4%) with interferon beta-1b, 117 (1.3%) with alemtuzumab, 36 (.4%) with siponimod, 24 (.3%) with cladribine, and 12 (.1%) with rituximab. Reports were mostly made by patients (78.3%) and highest in fifth and sixth decades of life. OpenFDA analyses showed increased ROR (ROR 95% confidence interval) of alopecia in females with teriflunomide (18.00, 17.12-18.93), alemtuzumab (1.43, 1.16-1.76), dimethyl fumarate (1.26, 1.18-1.34), and ocrelizumab (1.28, 1.11-1.49). Increased ROR in males was associated with teriflunomide (24.65, 20.72-29.31). CONCLUSION We identified many reports of alopecia for DMTs in addition to teriflunomide. Within the limitations of the database, increased RORs of alopecia were observed for females treated with alemtuzumab, dimethyl fumarate, and ocrelizumab. The source of reporting was largely driven by female patients. Possible alopecia, even if transient, should be considered during patient education when starting DMTs.

show abstract

Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women

et al. 2022

View full text Add to dashboard Cite

Multiple sclerosis and alopecia areata

Cited by 3 publications

References 0 publications

Associations between alopecia areata and multiple sclerosis: a report of two cases and review of the literature

Associations between alopecia areata and multiple sclerosis: a report of two cases and review of the literature

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

Immune-mediated diseases and subsequent risk of alopecia areata in a prospective study of US women

Contact Info

Product

Resources

About